Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...

Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupusNEW YORK, Feb. 12, 2025 ...

Like Nurtec, it targets the CGRP protein, which plays a role in migraine onset by triggering inflammation and pain. Ubrelvy works by blocking CGRP’s action, helping to reduce migraine symptoms.

Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance(5) provided on December 17, 2024. The ...

You have the ability to fix things in this action RPG, though, and you can do so by helping heal the Homunculi and then using their abilities and skills to traverse the world and fight off other foes.

Sometimes you just want to watch someone kick butt. That's where the best action movies come in, with their endless supply of fights, chases, and explosions. No genre packs more punches — and ...

Pfiz­er will pay near­ly $60 mil­lion to set­tle claims that its sub­sidiary Bio­haven used il­le­gal kick­backs to dri­ve sales of its mi­graine med­i­cine Nurtec ODT … ...

Pfizer will pay nearly $60 million to settle allegations that Biohaven, a company it acquired, paid kickbacks to healthcare professionals to encourage them to prescribe its migraine drug Nurtec ODT, ...

Pfizer ended the Nurtec speaker programs after paying $11.5 billion to buy Biohaven. "Patients deserve to know that their doctor is prescribing medications based on their doctor’s medical ...